Breaking News

Chemomab and AGC Biologics Partner to Manufacture CM-101 for Phase II/III

AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen to support clinical testing and launch readiness.

Author Image

By: Charlie Sternberg

Associate Editor

Chemomab Therapeutics Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), have entered an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH).   Under terms of the agreeme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters